Brady Collins
The rabies vaccine is an immunising agent that contains a deactivated virus strain. When injected, it stimulates the immune system to produce protective antibodies. The deactivated rabies virus has been used as a vector for vaccines against SARS-CoV-2, influenza, Ebola, and Lassa fever. The vaccine has been shown to be effective in protecting against these diseases in animal models and non-human primates. The deactivated rabies vaccine is also used to prevent rabies in dogs, with mild and temporary reactions, while serious reactions are rare.
| Characteristics | Values |
|---|---|
| Does the rabies vaccine contain a deactivated rabies virus? | Yes |
| Type of vaccine | Deactivated/inactivated |
| Function | Immunising agent |
| Use | Stimulates the immune system to produce protective antibodies |
| Side effects | Mild: Localized soreness or tenderness at the injection site. Rare: Anaphylaxis, sudden behavioural changes, autoimmune disorders, loss of coordination, muscle tremors, seizures |
| Animals used in trials | Hamsters, non-human primates, dogs |
Explore related products
What You'll Learn
Rabies vaccine side effects in dogs
Rabies is a highly contagious and often fatal viral disease that affects dogs, cats, and other mammals, including humans. It is transmitted through contact with an infected animal's saliva or nervous tissue, typically via bites or scratches. The good news is that rabies in dogs is entirely preventable with proper vaccination. All rabies vaccines administered in the US and Canada are inactivated or killed, meaning the virus has been processed and cannot cause disease.
The rabies vaccine is highly effective, and it is rare for vaccinated dogs to become infected. However, as with any vaccine, there is a small risk of side effects. These side effects are usually mild and related to the stimulation of the dog's immune system. Common side effects include mild fever, loss of appetite, and mild to moderate loss of energy for 24 to 36 hours after vaccination. Some dogs may also experience soreness and mild swelling at the injection site, which can last for a couple of weeks. In rare cases, a small circular area of hair loss may develop at the injection site. It is important to note that some dogs may not experience any side effects at all.
If side effects do occur, they typically start within an hour of vaccination and subside within one to two days. If they worsen or persist beyond a few days, or if your dog develops severe or abnormal reactions, contact your veterinarian for advice. In the rare case of a severe reaction, immediate veterinary care is necessary.
To maintain immunity, dogs typically require follow-up booster doses after the initial vaccination. These boosters are usually given annually and then once every one to three years, depending on the specific vaccine.
In summary, while there is a small risk of side effects with the rabies vaccine, the benefits of protecting your dog from this deadly disease far outweigh the risks.
Vaccines in USA and Europe: What's the Difference?
You may want to see also
Explore related products
CORAVAX, a single-dose rabies vaccine
Rabies vaccines are known to have an excellent safety profile, and they can be administered to pregnant women, children, and the immunocompromised. They also induce lifelong immunity and are less reactogenic. CORAVAX is a deactivated rabies-virus-vectored COVID-19 vaccine that has been proven to be highly efficacious in preventing lung inflammation in a hamster model. It is an adjuvanted inactivated vaccine generated using the SAD-B19 Rabies vaccine strain encoding the S1 subunit of SARS-CoV-2.
A single dose of CORAVAX induced high S1 and RBD IgG responses along with high virus-neutralizing antibodies against SARS-CoV-2. The vaccine also prevented weight loss, viral loads, disease, lung inflammation, and the cytokine storm in hamsters. In addition, CORAVAX was found to induce high RABV VNA, making it a potential vaccine against rabies as well.
The production of CORAVAX is expected to be facile, as it would follow the existing RABV vaccine manufacturing facilities and technologies. A phase I human clinical trial is being conducted in India by Bharat Biotech International Ltd., with plans for a follow-up phase I study in the US.
In summary, CORAVAX is a promising dual-antigen vaccine candidate for clinical evaluation against SARS-CoV-2 and the rabies virus. It has the potential to provide long-term protection against both viruses, making it a valuable tool in the fight against these diseases.
California Bans Nearly All Medical Vaccine Exemptions
You may want to see also
Explore related products
$22.44 $39.95
FILORAB1, another single-dose rabies vaccine
FILORAB1 is a single-dose rabies vaccine that has been evaluated in nonhuman primate challenge models. In a study comparing FILORAB1 with CORAVAX, a single-dose rabies-virus-vectored COVID-19 vaccine, both vaccines induced strong rabies virus neutralizing antibody (VNA) titers exceeding protective levels. However, the CORAVAX group showed higher VNA titers and significantly less weight loss compared to the FILORAB1 group.
The study also evaluated the immunogenicity and efficacy of the vaccines against SARS-CoV-2. The CORAVAX-vaccinated animals showed superior protection against weight loss and lung inflammation, reduced lung viral loads, and alleviated the lung cytokine storm compared to the FILORAB1 group. The CORAVAX vaccine induced high SARS-CoV-2 S1-specific and virus-neutralizing antibodies (VNAs), while the FILORAB1 group had lower VNA titers and some VNAs were only detected after the challenge.
The FILORAB1 vaccine has been shown to provide complete protection in nonhuman primate challenge models for Ebola. This indicates that the vaccine induces antibodies with neutralizing capabilities. However, in the context of SARS-CoV-2, the FILORAB1 vaccine did not demonstrate the same level of protection as CORAVAX, suggesting that it may be less effective against this specific virus.
Overall, while FILORAB1 is a promising single-dose rabies vaccine, it may have varying levels of efficacy against different viruses. Further studies are needed to evaluate its effectiveness in preventing other diseases.
Vaccinating Your Baby in Connecticut: What You Need to Know
You may want to see also
Explore related products
Deactivated rabies-based H5 vaccine for cattle
In early 2024, the HPAI H5N1 clade 2.3.4.4b virus was detected among dairy cows in Texas, causing significant morbidity and a substantial reduction in milk production and quality. The virus has spread to over 900 farms in 16 US states and has also been found in other animals, including wild mammals, domesticated cats and dogs, and other livestock. At least 67 human H5N1 infections have been reported, and there are concerns that the outbreak will not be contained with traditional farm biosecurity measures alone. To address this issue, researchers developed a deactivated rabies-virus-based H5 vaccine for cattle, known as RABV-H5.
The RABV-H5 vaccine was created by cloning the synthetic full-length codon-optimized HA ORF of the Influenza virus A/Viet Nam 1203/2004(H5N1) isolate into the well-established rabies vaccine vector (BNSP333) between the N and P genes. The expression of the H5 and rabies G proteins in RABV-H5-infected cells was confirmed through immunofluorescence using specific antibodies. The vaccine was then evaluated for its immunogenicity and safety in cattle.
To assess the immunogenicity of the BNSP333-H5 vaccine, researchers randomly assigned 12 heifer calves to three vaccination groups: Group A received the RABV-H5 vaccine with SEPPIC adjuvant in a prime-only regimen, Group B received the vaccine without adjuvant in a prime-boost regimen, and Group C received the vaccine with SEPPIC adjuvant in a prime-boost regimen. The vaccine was Betapropiolactone (BPL) inactivated, and a 100 µg dose was injected subcutaneously. This dose was selected based on previous immunogenicity studies using the RABV-based vaccine in non-human primates.
The results showed that the deactivated rabies-virus-based H5 vaccine was well-tolerated and elicited neutralizing antibodies against both clade-1 and clade-2.3.4.4b H5N1 viruses. The immune responses were durable for at least 200 days and were unaffected by pre-existing RABV immunity. Additionally, the vaccine induced a dose-dependent immune response, with higher doses resulting in stronger and more sustained antibody levels.
BCG Vaccine: Why Does It Leave a Scar?
You may want to see also
Explore related products
Deactivated rabies-based Lassa fever virus vaccine for non-human primates
Rabies vaccines have been used as a vector for vaccines against other viruses, including Ebola, SARS-CoV-2, and influenza. In 2024, a group of researchers published a paper on the efficacy of a deactivated rabies virus-based vaccine against Lassa fever virus (LASV) in non-human primates (NHPs). LASV is a highly dangerous virus that causes Lassa fever, a severe hemorrhagic disease that is endemic to West Africa and causes considerable morbidity and mortality. There are currently no FDA-approved vaccines or treatments for LASV.
The deactivated rabies-based vaccine, named LASSARAB, encodes the glycoprotein precursor (GPC) of LASV. In the study, NHPs were administered a two-dose regimen of LASSARAB or an irrelevant RABV-based vaccine as a negative control. The NHPs immunized with LASSARAB developed strong humoral responses to LASV-GPC, and all survived to the study endpoint, while the NHPs in the control group did not. This demonstrated that LASSARAB could protect against severe disease and death in a lethal NHP model of LF.
The study also measured antibody responses against LASV-GPC and RABV-G through enzyme-linked immunosorbent assay (ELISA). Antibody EC50 and endpoint titers were measured over time, with neutralizing antibody titers peaking between days 14 to 21 post-challenge and persisting through day 28. These results indicated that LASSARAB is a promising vaccine candidate for further development, as it was able to induce strong immune responses and protect NHPs from lethal LASV infection.
The development of a safe and effective LASV vaccine is crucial given the severity of Lassa fever and the lack of preventative measures currently available. The successful use of a deactivated rabies virus as a vaccine vector for LASV in NHPs demonstrates the potential for this approach in combating other deadly viruses.
Rabies Vaccine: Why Do Puppies Get Big Bumps?
You may want to see also
Frequently asked questions
Yes, the rabies vaccine contains a deactivated rabies virus strain. This deactivated virus stimulates the immune system to produce antibodies that protect against the active rabies virus.
The rabies vaccine is an essential immunising agent that protects individuals from contracting the deadly rabies virus. It is also crucial for complying with international travel rules.
Most individuals tolerate the rabies vaccine well, experiencing only mild and temporary reactions such as localized soreness or tenderness at the injection site. However, rare but serious side effects like anaphylaxis, behavioural changes, and autoimmune disorders can occur in some cases.
![Rabies [DVD] (DVD) JAPANESE EDITION](https://m.media-amazon.com/images/I/81AimwEWlYL._AC_UL320_.jpg)
